Furthermore, expression of IL21 mRNA was lower in blood cells from SPMS patients treated with mitoxantrone, suggesting that inhibition of TFH function may be an effect of mitoxantrone in SPMS. This evidence concerns the gene IL21 and secondary progressive multiple sclerosis.